Edited by: Thomas Bieber
Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial
Article first published online: 4 JUN 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Volume 68, Issue 7, pages 949–952, July 2013
How to Cite
Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy 2013; 68: 949–952., , , , , , , , .
This study was financially supported by the urticaria network e.V. (UNEV, www.urtikaria.net) and an unrestricted grant from J. Uriach y Compania., S.A. Barcelona, Spain.
- Issue published online: 15 JUL 2013
- Article first published online: 4 JUN 2013
- Manuscript Accepted: 28 FEB 2013
- platelet-activating factor;
- urticaria pigmentosa
Mastocytosis is frequently associated with mast cell-mediated symptoms which require relieving medication. While second generation antihistamines (sgAHs) are the first line therapeutic strategy to treat mast cell mediator-related symptoms, controlled clinical trials on how they improve quality of life have not been performed.
This randomized, double-blind, placebo-controlled, cross-over trial assessed rupatadine 20 mg daily in the treatment of mastocytosis symptoms in 30 adult patients. Symptoms were assessed by a visual analogue scale (VAS) and symptom specific quality of life questionnaire (ItchyQoL).
The mean ItchyQoL total score and VAS symptom score were significantly improved in the rupatadine treatment phase compared with placebo. There were also significant reductions from placebo in the severity of itch, wheal and flare, flushing, tachycardia and headache but not gastrointestinal symptoms.
In this first comprehensive trial of a sgAH in mastocytosis, rupatadine 20 mg daily for 4 weeks significantly controlled symptoms and improved patients' quality of life.